Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Whitehawk Therapeutics (WHWK) Cost of Revenue (2022 - 2025)

Historic Cost of Revenue for Whitehawk Therapeutics (WHWK) over the last 4 years, with Q1 2025 value amounting to $760000.0.

  • Whitehawk Therapeutics' Cost of Revenue rose 1656.44% to $760000.0 in Q1 2025 from the same period last year, while for Sep 2025 it was $1.5 million, marking a year-over-year decrease of 5096.49%. This contributed to the annual value of $3.0 million for FY2024, which is 765.4% up from last year.
  • As of Q1 2025, Whitehawk Therapeutics' Cost of Revenue stood at $760000.0, which was up 1656.44% from $790000.0 recorded in Q4 2024.
  • Over the past 5 years, Whitehawk Therapeutics' Cost of Revenue peaked at $927000.0 during Q4 2023, and registered a low of $179000.0 during Q1 2022.
  • Moreover, its 4-year median value for Cost of Revenue was $656000.0 (2023), whereas its average is $609846.2.
  • As far as peak fluctuations go, Whitehawk Therapeutics' Cost of Revenue surged by 31756.76% in 2023, and later tumbled by 1477.89% in 2024.
  • Over the past 4 years, Whitehawk Therapeutics' Cost of Revenue (Quarter) stood at $222000.0 in 2022, then soared by 317.57% to $927000.0 in 2023, then dropped by 14.78% to $790000.0 in 2024, then decreased by 3.8% to $760000.0 in 2025.
  • Its Cost of Revenue was $760000.0 in Q1 2025, compared to $790000.0 in Q4 2024 and $804000.0 in Q3 2024.